Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Phase I Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia - Drug Trials For Money - Paid Clinical Trials

Phase I Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

Phase I Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Conditions:   Acute Lymphoblastic Leukemia, in Relapse;   Acute Lymphoblastic Leukemia, Refractory;   Pediatric ALL
Interventions:   Biological: CD19-CAR(Mem) T-cells;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Mesna;   Device: CliniMACS;   Procedure: Leukapheresis
Sponsor:   St. Jude Children’s Research Hospital
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 12, 2021 / by / in
Comments